Form 8-K - Current report:
SEC Accession No. 0001641172-25-010873
Filing Date
2025-05-15
Accepted
2025-05-15 16:05:38
Documents
17
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43110
2 EX-99.1 ex99-1.htm EX-99.1 50398
3 GRAPHIC form8-k_001.jpg GRAPHIC 3989
4 GRAPHIC ex99-1_001.jpg GRAPHIC 12752
  Complete submission text file 0001641172-25-010873.txt   348908

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cycc-20250514.xsd EX-101.SCH 3743
6 XBRL DEFINITION FILE cycc-20250514_def.xml EX-101.DEF 26581
7 XBRL LABEL FILE cycc-20250514_lab.xml EX-101.LAB 36613
8 XBRL PRESENTATION FILE cycc-20250514_pre.xml EX-101.PRE 25205
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5748
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25952700
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)